Valeant wins first round in $445M gam­ble on bro­dalum­ab ap­proval

5 years ago
R&D

Mer­ck KGaA blue­prints a $115M 'col­lab­o­ra­tion cam­pus' for Mass­a­chu­setts

5 years ago
R&D

Mer­ck-backed Quar­tet places biotech vet Ger­hard Koenig at the helm

5 years ago
R&D

Cel­gene signs Jounce as its new biotech star in $2.6B ‘im­muno-on­col­o­gy 2.0’ pact

5 years ago
R&D

Cel­gene EVP Bag­ger gets a plum as­sign­ment on Trump team

5 years ago
R&D

Biotech vet Gould lands $55M start­up round for a new Third Rock plat­form biotech

5 years ago
R&D

No­var­tis’ cam­paign to sweep biosim­i­lar ap­provals hits a set­back

5 years ago
R&D

Brain­storm’s ral­ly fiz­zles af­ter in­vestors turn sour on ques­tion­able ALS da­ta

5 years ago
R&D

Play­ing de­fense, Roche los­es megafran­chise gam­bit as Gazy­va flunks head-to-head with Rit­ux­an

5 years ago
R&D

With cash run­ning low, lit­tle Evoke los­es a cru­cial PhI­II gam­ble

5 years ago
R&D

Which big bio­phar­ma com­pa­nies put R&D as their top pri­or­i­ty?

5 years ago
R&D

No min­is­ter: UK biotech com­mu­ni­ty los­es its ded­i­cat­ed gov­ern­ment min­is­ter

5 years ago
R&D

Zio­pharm craters on re­port of pa­tient death in gene ther­a­py study

5 years ago
R&D

As­traZeneca says it is prun­ing staff at Med­Im­mune, its bi­o­log­ics R&D cen­ter

5 years ago
R&D

FDA re­view de­tails sui­cides, car­dio risks linked to Valeant’s $100M drug bro­dalum­ab

5 years ago
R&D

Q2 ven­ture in­vest­ing slows a tad, but the big mon­ey still flows in­to biotech

5 years ago
Financing
R&D

CAR-T play­er Juno grabs a PhII com­bo drug in $10M add-on deal

5 years ago
R&D

Mar­tin Shkre­li will have his day(s) in court - next June

5 years ago
People

Kad­mon sticks a $100M toe in chilly mar­ket wa­ters

5 years ago
R&D

San­thera’s Duchenne drug hits a road­block at the FDA, and one an­a­lyst sees an­oth­er bad sign for Sarep­ta

5 years ago
R&D

And then there were 4: Juno adds an­oth­er vic­tim in CAR-T death tal­ly

5 years ago
R&D

Po­laris is piec­ing to­geth­er a new, $400M-plus biotech fund as good times roll

5 years ago
R&D

Biosim­i­lars go 2-0 in an FDA dou­ble-head­er fa­vor­ing No­var­tis, Am­gen

5 years ago
R&D

The 15 top R&D spenders in the glob­al bio­phar­ma busi­ness: 2016

5 years ago
R&D
Special
First page Previous page 441442443444445446447 Next page Last page